论文部分内容阅读
在临床确诊为病毒性心肌炎35例患者中,经核素心血管造影,观察到口服黄芪组(m=10,包括1例一般药物治疗3月无效患者)治疗3月与静脉滴注赞芪组(n=15,包括1例口服黄芪3月无效患者)治疗8周后静态左室喷血分数(LVEF)、相对搏出量(RSV)及相对舒张末期容量(REDV)明显高于治疗前。上述指标在治疗后的增加量亦分别显著大于12例一般治疗(8例治疗3月,4例治疗3周)的两个对照组。室壁活动异常的改善在口服黄芪组亦明显优于其相应的对照组。结果提示黄芪能改善病毒性心肌炎患者的心功能状态。
In the clinical diagnosis of viral myocarditis in 35 patients, by radionuclide cardiovascular angiography, was observed in the oral Astragalus group (m = 10, including 1 case of general medical treatment ineffective in patients with March) March treatment with intravenous infusion of Yan Qi group (LVEF), relative stroke volume (RSV) and relative end-diastolic volume (REDV) were significantly higher than those before treatment after treatment for 8 weeks (n = 15, including 1 case of astragalus in March ineffective). The increase of these indexes after treatment was also significantly greater than the two control groups of 12 patients with general treatment (8 patients treated with 3 months and 4 patients treated with 3 weeks). Improvement of abnormal wall activity in the oral administration of astragalus group also significantly better than its corresponding control group. The results suggest that astragalus can improve the cardiac function in patients with viral myocarditis.